Can Stem Cell Therapy cure Joint Pain?
Stem cell therapy is not a cure for joint pain, because most chronic joint pain comes from conditions such as osteoarthritis, tendon degeneration or old injuries that no treatment can fully reverse.

What regenerative treatment can do is reduce pain, calm inflammation and improve function, which for many patients means walking, working, exercising and sleeping better, and in some cases postponing surgery. The strongest evidence comes from knee osteoarthritis: a 2024 meta-analysis of randomized controlled trials found that mesenchymal stem cell (MSC) injections reduced pain more than hyaluronic acid at 12 months and improved function, and a randomized trial of umbilical cord MSCs found better pain and function scores at 12 months than hyaluronic acid. At Stem Cell Mexico, joint protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, applied by direct injection with ultrasound guidance, often together with platelet-rich plasma (PRP). Results vary from patient to patient, and treatment works best combined with exercise and weight management.
This guide explains what causes joint pain, what regenerative treatment can realistically change, how it compares with other options and how to decide whether it fits your situation.
Why joint pain is rarely "curable"
Joints are made of several tissues working together: cartilage that covers the ends of the bones, the synovial membrane that produces lubricating fluid, ligaments, tendons, muscles and the bone beneath the cartilage. Pain can come from any of them.
The most common causes of chronic joint pain in adults are:
- Osteoarthritis: gradual wear and remodeling of cartilage and bone, with inflammation of the joint lining. It is the most common joint condition worldwide.
- Tendinopathies: degeneration of tendons around the shoulder, elbow, hip, knee or ankle.
- Old injuries: meniscus or labrum tears, ligament sprains and cartilage defects that never fully healed.
- Inflammatory arthritis: such as rheumatoid arthritis, which is driven by the immune system.
Adult cartilage has very little ability to regenerate, and changes in bone shape do not reverse. For these reasons, the goal of any treatment, including regenerative medicine, is to control pain, improve function and protect the joint, not to return it to the condition it had at 20.
What regenerative treatment can change
MSCs from Wharton's jelly act mostly through paracrine signaling: they release anti-inflammatory and trophic factors that may:
- Reduce inflammation inside the joint and in the synovial membrane.
- Modulate pain signaling.
- Support the remaining cartilage cells and the healing activity of tendons and ligaments.
- Improve the joint environment, which can make movement and exercise easier.
PRP, prepared from your own blood, adds concentrated growth factors and is often combined with the cells.
For patients, these effects may translate into less pain, less stiffness, better range of motion and more confidence in daily activities.
What the evidence shows
Knee osteoarthritis
- Meta-analysis (2024): a systematic review of randomized controlled trials published in the Journal of Orthopaedic Translation found that MSC therapy reduced pain more than hyaluronic acid at 12 months and improved function on WOMAC scores, with no difference in serious adverse events compared with control treatments.
- Umbilical cord MSCs: a randomized controlled phase I/II trial published in Stem Cells Translational Medicine compared umbilical cord MSCs with hyaluronic acid in knee osteoarthritis. Patients who received repeated cord MSC injections had significantly better pain and function scores at 12 months, with no serious adverse events attributed to the cells.
Other joints and tendons
Clinical studies of cell-based treatments for the hip, shoulder, ankle and tendons such as the rotator cuff and Achilles tendon report improvements in pain and function in many patients. Sports medicine experts, in the 2020 NBA Orthobiologics Consensus Statement, recognized the growing role of cell-based and other biologic treatments for athletes and recommended careful patient selection and image-guided application.
How it compares with other options
The NICE guideline on osteoarthritis (NG226) recommends exercise, weight management and education as the foundation of care, with medications such as topical and oral anti-inflammatory drugs when needed. Other common options include:
- Physical therapy: essential for strength, mobility and joint protection.
- Corticosteroid injections: fast short-term relief that usually lasts weeks; repeated injections may affect cartilage and tendons.
- Hyaluronic acid: lubricating injections with variable benefit.
- PRP: growth-factor injections from your own blood.
- Joint replacement: an effective option for advanced, bone-on-bone arthritis.
Regenerative treatment sits between conservative care and surgery. For many patients with mild to moderate osteoarthritis or chronic tendon problems, it offers a minimally invasive option that may reduce pain for a longer period than a steroid injection and may help postpone surgery.
Who tends to benefit most
- Mild to moderate osteoarthritis (Kellgren-Lawrence grades 2 to 3), with some cartilage remaining.
- Chronic tendinopathies that have not improved with a structured rehabilitation program.
- Partial tears of tendons or ligaments, confirmed by imaging.
- Patients who stay active and commit to exercise after treatment.
- Healthy body weight or active weight management, since every extra kilogram adds load to weight-bearing joints.
Patients with advanced bone-on-bone arthritis and major deformity can still be evaluated, but the chance of meaningful benefit is lower, and joint replacement may be the better long-term option.
Joint by joint
- Knee: the most studied joint, with randomized trials in osteoarthritis. Treatment can target the joint space and, when indicated, the meniscus or surrounding tendons.
- Hip: a deep joint that requires precise image guidance; often treated for early osteoarthritis or labral problems.
- Shoulder: commonly treated for rotator cuff tendinopathy, partial tears and early osteoarthritis.
- Ankle: treated for osteoarthritis after old sprains or fractures, and for Achilles tendon problems.
- Elbow and wrist: treated for tendinopathies such as tennis elbow and for arthritis of the small joints.
Each joint has its own anatomy and loading, which is why the number of cells and the injection technique are adapted to the joint and to your imaging.
What our patients usually receive
Based on the treatment plans our team prepares for patients, a typical joint protocol at Stem Cell Mexico includes:
- 20 to 40 million Wharton's jelly MSCs per joint, applied by direct injection with ultrasound guidance.
- Platelet-rich plasma (PRP) in many plans, applied together with the cells.
- One night at our facilities with nursing and medical monitoring.
- Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
- Your recent imaging: an MRI of the area no older than three months is requested.
One joint typically costs $3,900 to $6,000 USD, and plans for two or more joints typically cost $6,000 to $9,000 USD.
Based on what patients tell us, many begin to notice improvement within a few days to a few weeks after the application, while others improve more gradually over the following months. Our team stays in contact after treatment to follow your progress and decide whether a second application or a PRP session could help.
Safety
Randomized trials in knee osteoarthritis have not shown more serious adverse events with MSCs than with control treatments. The most common effects are temporary pain, swelling or stiffness in the treated joint for a few days. Infection is rare when the procedure is performed with sterile technique and image guidance. No medical treatment is free of risk, which is why screening, sterile technique and follow-up are part of every protocol.
How to get the most from treatment
- Follow the activity plan: relative rest for a few days, then progressive exercise.
- Work with a physical therapist on strength and mobility.
- Manage weight, especially for knees and hips.
- Avoid anti-inflammatory painkillers in the period the doctor indicates around treatment.
- Track your progress with simple measures: pain scores, walking distance, stairs or sleep.
- Plan your return to sport gradually, increasing intensity only when strength and comfort allow.
Who may not be a candidate
- Active infection in or near the joint.
- Cancer within the past five years.
- Unstable joints or complete ruptures that need surgical repair.
- Uncontrolled diabetes or other conditions that need stabilization first.
Questions to ask during your evaluation
- What is causing my joint pain?
- What stage is my osteoarthritis, based on my imaging?
- How many cells are recommended, and will PRP be included?
- What can I realistically expect for pain and function?
- What rehabilitation should I follow afterward?
Bottom line
Stem cell therapy does not cure joint pain, but it can reduce pain and improve function for many patients, especially those with mild to moderate knee osteoarthritis, where randomized trials show better results than hyaluronic acid at 12 months and a favorable safety profile. At Stem Cell Mexico, Wharton's jelly MSCs, often combined with PRP, are applied with ultrasound guidance as part of a plan that includes exercise and follow-up, and results vary from patient to patient. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your joints, goals and medical history.
References
- Tabet CG et al. Advanced therapy with mesenchymal stromal cells for knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Translation, 2024 (opens in a new tab)
- Matas J et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Stem Cells Translational Medicine, 2019 (opens in a new tab)
- NICE guideline NG226: Osteoarthritis in over 16s, diagnosis and management (opens in a new tab)
- Cole BJ et al. The 2020 NBA Orthobiologics Consensus Statement. Orthopaedic Journal of Sports Medicine, 2021 (opens in a new tab)
